RAF/RAS oncogenes and mismatch-repair status
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Genes of the RAF family encode kinases that are regulated by Ras and mediate cellular responses to growth signals. Activating mutations in one RAF gene, BRAF, have been found in a high proportion of melanomas and in a small fraction of other cancers. Here we show that BRAF mutations in colorectal cancers occur only in tumours that do not carry mutations in a RAS gene known as KRAS, and that BRAF mutation is linked to the proficiency of these tumours in repairing mismatched bases in DNA. Our results not only provide genetic support for the idea that mutations in BRAF and KRAS exert equivalent effects in tumorigenesis, but also emphasize the role of repair processes in establishing the mutation spectra that underpin human cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prevalence of BRAF V600E mutations in mCRC is 8–10%, and they occur only in KRAS-WT mCRC [159,160].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [160]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Self-citationStabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines
Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., & Polakis, P. (1997) · Science · doi:10.1126/science.275.5307.1790 · Cited by 1,223
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Sparks, A. B., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · PubMed · Cited by 1,008
Self-citationDifferential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456
Mechanisms underlying losses of heterozygosity in human colorectal cancers
Thiagalingam, S., Laken, S., Willson, J. K. V., Markowitz, S. D., Kinzler, K. W., Vogelstein, B., & Lengauer, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051625398 · Cited by 228
Self-citationPrevalence of somatic alterations in the colorectal cancer cell genome
Wang, T.-L., Rago, C., Silliman, N., Ptak, J., Markowitz, S., Willson, J. K. V., Parmigiani, G., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261714699 · Cited by 177
Self-citationOncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors
Storm, S. M., & Rapp, U. R. (1993) · Toxicology Letters · doi:10.1016/0378-4274(93)90056-4 · Cited by 53
Research works printed but not linked: 2
- Sparks, A. B., Morin, P. J., Vogelstein, B. & Kinzler, K. W. Cancer Res. 58, 1130–1134 (1998).
- Markowitz, S. J. Clin. Oncol. 18 (suppl.), 75–80 (2000).
Cited by
Items 701–800 of 999
Bougatef, K., Ouerhani, S., Moussa, A., Kourda, N., Coulet, F., Colas, C., Lahely, Y. B., Najjar, T., Jilani, S. B., Elgaaïed, A. B. A., et al. (2008) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2008.06.016 · Cited by 21
The BRAF mutation is associated with the prognosis in colorectal cancer
Ahn, T. S., Jeong, D., Son, M. W., Jung, H., Park, S., Kim, H., Bae, S. B., Kim, H. J., Jeon, Y., Lee, M. S., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1735-y · Cited by 25
“B-Raf is a member of the Raf kinase family that regulates the Ras/Raf/MEK/ERK kinase pathway and is involved in division, differentiation, and secretion (Rajagopalan et al. 2002; Davies et al. 2002).”
BackgroundRyslik, G., Cheng, Y., Cheung, K.-H., Bjornson, R. D., Zelterman, D. A., Modis, Y., & Zhao, H. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-231 · Cited by 22
“ypically result in constitutively elevated kinase activity and have been found in a wide range of cancers such as metastatic melanoma, ovarian carcinoma and colorectal carcinoma (Davies et al., 2002; Rajagopalan et al., 2002; Hingorani et al., 2003; Sjblom et al., 2006; Greenman et al., 2007; Andreu-Prez et al., 2011)…”
BackgroundThe hMSH2 and hMLH1 Genes in Hereditary Nonpolyposis Colorectal Cancer
Lynch, P. M. (2009) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2009.08.002 · Cited by 27
Huang, C., Frankel, W. L., Doukides, T. P., Zhou, X., Zhao, W., & Yearsley, M. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.06.011 · Cited by 23
“The BRAF mutation frequency in rectal microvesicular HPs in our study was higher (100%) than the reported 77% and 50% in the distal and the proximal colon, respectively [12].”
BackgroundResultTargeting Mismatch Repair defects: A novel strategy for personalized cancer treatment
Begum, R., & Martin, S. A. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.11.026 · Cited by 26
Non‐V600E BRAF mutations and EGFR signaling pathway in colorectal cancer
Osumi, H., Shinozaki, E., Wakatsuki, T., Suenaga, M., Ichimura, T., Ogura, M., Takahari, D., Ooki, A., Suzuki, T., Ota, Y., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32320 · Cited by 25
“In our study, two cases of RAS and BRAF co-MT were observed, although BRAF MT and RAS MTs are usually considered mutually exclusive.(24) The reason why we found patients with RAS and BRAF co-MT may be that kinase activity is different between BRAF and BRAF MTs.”
BackgroundPrognostic and predictive value of KRAS mutation number in metastatic colorectal cancer
Ucar, G., Ergun, Y., Aktürk Esen, S., Acikgoz, Y., Dirikoc, M., Esen, İ., Bal, Ö., & Uncu, D. (2020) · Medicine · doi:10.1097/md.0000000000022407 · Cited by 19
“There are 3 members of the RAS gene superfamily: KRAS, HRAS, and NRAS, and approximately 40% of CRCs contain KRAS mutations.([9,10]) While KRAS exon 2 mutations constitute the majority of KRAS mutations, exon 3 and exon 4 mutations constitute only 1% to 4% of CRCs.”
BackgroundChung, C. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211005525 · Cited by 28
“Similar to its original version published in 2014, this update aims to provide a succinct summary on the use of prognostic and/or predictive biomarkers associated with CRC. Evidence is collected from published literature and commonly accepted oncology guidelines and is presented in an application-based format.”
BackgroundInfluentialCurrent controversies in the management of metastatic colorectal cancer
Vera, R., Alonso, V., Gallego-Plazas, J., González‐Flores, E., Guillén‐Ponce, C., Pericay, C., Rivera, F., Safont, M. J., & Valladares‐Ayerbes, M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2808-6 · Cited by 25
“BRAF signals through the same pathway as KRAS, but BRAF and KRAS mutations are mutual exclusivity [48].”
BackgroundBurger, M., Denzinger, S., Hammerschmied, C. G., Tannapfel, A., Maderstorfer, A., Wieland, W. F., Hartmann, A., & Stoehr, R. (2006) · European Urology · doi:10.1016/j.eururo.2005.11.031 · Cited by 21
Symvoulakis, E. K., Zaravinos, A., Panutsopulos, D., Zoras, O., Papalambros, E. L., Sigala, F., & Spandidos, D. A. (2007) · The International Journal of Biological Markers · doi:10.1177/172460080702200102 · Cited by 23
“The low frequency of BRAF mutations observed in mismatch-repair–proficient tumors might be explained by the absence of MLH1 hypermethylation (15, 35, 36).”
BackgroundInfluentialAbsence of microsatellite instability and BRAF ( V600E ) mutation in testicular germ cell tumors
Cárcano, F. M., Lengert, A. V. H., Vidal, D. O., Scapulatempo‐Neto, C., Queiroz, L., Marques, H., Baltazar, F., Berardinelli, G. N., Martinelli, C. M. S., da Silva, E. C. A., et al. (2016) · Andrology · doi:10.1111/andr.12200 · Cited by 25
“BRAF is activated by hotspot mutations, mainly V600E, which has been found in melanomas and other types of cancer (Rajagopalan et al., 2002; Michaloglou et al., 2008).”
BackgroundGene silencing in phenomena related to DNA repair
Mukai, T., & Sekiguchi, M. (2002) · Oncogene · doi:10.1038/sj.onc.1206095 · Cited by 23
“Recently, Rajagopalan et al. (2002) found that in colorectal cancers, Braf mutations occur only in tumors that do not carry mutations in the K-ras.”
BackgroundSaunders, A. S., Bender, D. E., Ray, A. L., Wu, X., & Morris, K. T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247233 · Cited by 27
“Subsequent mutations in the proto-oncogene KRAS are often seen at the early adenoma stage of CRC development [67, 68].”
BackgroundKościuszko, M., Buczyńska, A., Kretowski, A. J., & Popławska‐Kita, A. (2023) · Cancers · doi:10.3390/cancers15123182 · Cited by 27
Epithelial Morphogenesis and Intestinal Cancer: New Insights in Signaling Mechanisms
Fré, S., Vignjevic, D. M., Schoumacher, M., Duffy, S., Janssen, K., Robine, S., & Louvard, D. (2008) · Advances in cancer research · doi:10.1016/s0065-230x(08)00003-1 · Cited by 26
Characterization of heat-wave propagation through laser-driven Ti-doped underdense plasma
Tanabe, M., Nishimura, H., Ohnishi, N., Fournier, K. B., Fujioka, S., Iwamae, A., Hansen, S. B., Nagai, K., Girard, F., Primout, M., et al. (2009) · High Energy Density Physics · doi:10.1016/j.hedp.2009.06.006 · Cited by 22
Lynch syndrome: clinical, pathological, and genetic insights
Schneider, R. A., Schneider, C., Kloor, M., Fürst, A., & Möslein, G. (2012) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-012-0918-8 · Cited by 28
“The frequency of BRAFmutations in CRC ranges from 5% inMSS to 45% inMSI tumors [88].”
BackgroundKong, X., Qin, J., Li, Z., Vultur, A., Tong, L., Feng, E., Rajan, G. S., Liu, S., Lu, J., Liang, Z. T., et al. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob26081f · Cited by 24
Novel therapeutic agents in the treatment of metastatic colorectal cancer
Pai, S. G., & Fuloria, J. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i1.99 · Cited by 25
Dankner, M. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00195 · Cited by 24
Genetic unraveling of colorectal cancer
Rasool, S., Rasool, V., Naqvi, T., Ganai, B. A., & Shah, B. A. (2014) · Tumor Biology · doi:10.1007/s13277-014-1713-7 · Cited by 27
Mutational analysis of the BRAF gene in human tumor cells
Ueda, M., Eisaku, T. O. J. I., Nunobiki, O., Izuma, S., Okamoto, Y., Torii, K., & Noda, S. (2008) · Human Cell · doi:10.1111/j.1749-0774.2008.00046.x · Cited by 22
Raf Activation Is Regulated by Tyrosine 510 Phosphorylation in Drosophila
Fan, X., Li, J., Hickey, G., Tsurumi, A., Larson, K., Guo, D., Yan, S., Silver-Morse, L., & Li, W. X. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060128 · Cited by 22
“It has been reported that somatic mutations in BRaf are found in 60% of malignant melanomas and are also associated with other types of human cancers [3,4], which underscores the importance of this signaling pathway in tumorigenesis.”
BackgroundJohnston, L., Power, M., Sloan, P., Long, A. K., Silmon, A., Chaffey, B. T., Lisgo, A. J., Little, L., Vercauteren, E., Steiniche, T., et al. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2017-204629 · Cited by 23
Importance of serrated polyps in colorectal carcinogenesis
Liang, J., Bissett, I. P., Kalady, M. F., Bennet, A. E., & Church, J. M. (2012) · ANZ Journal of Surgery · doi:10.1111/j.1445-2197.2012.06269.x · Cited by 21
“43,46 Methylation of other mismatch repair genes is very rare (apoptosis-associated genes as p14, p16 and EpHB2).45,51,56,69–76 hMLH1 methylation has been detected in 36% of HPs, 70% of SSPs and 86–87% of sporadic MSI-H CRCs.56,69,77 These findings support the belief that SSAs/Ps are precursors of sporadic MSI-H CRCs.…”
BackgroundInfluentialChen, D., Huang, J.-F., Xia, H., Duan, G., Chuai, Z.-R., Yang, Z., Fu, W., & Huang, Q. Y. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-7618-x · Cited by 22
Molecular Mechanisms of Colorectal Carcinogenesis
Roper, J., & Hung, K. E. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8412-7_2 · Cited by 30
“Inactivation of Fbxw7/hCdc4 in CRC cells results in a CIN phenotype due to a defect in execution of metaphase (Rajagopalan et al. 2004 ).”
BackgroundImmunohistochemical Detection of the BRAF V600E Mutant Protein in Colorectal Neoplasms
Vakiani, E., Yaeger, R. D., Brooke, S., Zhou, Y., Klimstra, D. S., & Shia, J. (2014) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000116 · Cited by 21
Spatio-temporal tumor heterogeneity in metastatic CRC tumors: a mutational-based approach
del Carmen, S., Sayagués, J. M., Bengoechea, Ó., Anduaga, M. F., Alcázar, J. A. S., Gervás, R., García, J., Órfão, A., Muñoz‐Bellvís, L., Sarasquete, M. E., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26081 · Cited by 23
“It is well known that RAS and BRAF mutations are mutually exclusive [35], but our study shows that the presence of either a KRAS or a BRAF mutation in primary tumor or at metastatic sites, does not preclude the presence of the other mutation in a different location.”
BackgroundDigiacomo, N., Bolzacchini, E., Veronesi, G., Cerutti, R., Sahnane, N., Pinotti, G., Bregni, M., Artale, S. A., Verusio, C., Crivelli, F., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.12.003 · Cited by 23
Huang, C., Teng, H., Chien, C., Lin, J.-K., & Yang, S.-H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065117 · Cited by 23
“In theMAPkinasepathway,KRAS/BRAFmutationsoccur inamutually exclusive manner [29–31].”
Low Frequency of BRAF Mutations in Endometrial and in Cervical Carcinomas
Moreno‐Bueno, G., Sánchez‐Estévez, C., Palacios, J., & Hardisson, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0284 · Cited by 21
Changing Pathology with Changing Drugs: Tumors of the Gastrointestinal Tract
Cervera, P., & Fléjou, J. (2011) · Pathobiology · doi:10.1159/000315535 · Cited by 24
Demes, M. C., Scheil-Bertram, S., Bartsch, H., & Fisseler‐Eckhoff, A. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2013.012 · Cited by 21
“The identification of mutationally activated KRAS and BRAF alleles in several tumor models supports the importance of this signaling pathway in cancer progression (35,36).”
BackgroundSerrated Adenoma: A Distinct Form of Non-Polypoid Colorectal Neoplasia?
Noffsinger, A. E., & Hart, J. A. L. (2010) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2010.03.012 · Cited by 20
BRAF in Metastatic Colorectal Cancer: The Future Starts Now
Orlandi, A., Calegari, M. A., Inno, A., Berenato, R., Caporale, M., Niger, M., Bossi, I. E., Bartolomeo, M. D., de Braud, F., & Pietrantonio, F. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.140 · Cited by 20
Morgan, Z., Chow, B. E., Strong, E. A., Tsai, S., Christians, K. K., Mogal, H., Gamblin, T. C., & Clarke, C. N. (2019) · Journal of Surgical Research · doi:10.1016/j.jss.2019.02.050 · Cited by 21
BAD Contributes to RAF-mediated Proliferation and Cooperates with B-RAF-V600E in Cancer Signaling
Polzien, L., Baljuls, A., Albrecht, M., Hekman, M., & Rapp, U. R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.177345 · Cited by 20
BRAF V600E Is a Determinant of Sensitivity to Proteasome Inhibitors
Zecchin, D., Boscaro, V., Médico, E., Barault, L., Martini, M., Arena, S., Cancelliere, C., Bartolini, A., Crowley, E. H., Bardelli, A., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0243 · Cited by 21
“are frequently associated to microsatellite instable (MSI) phenotype (44) .”
BackgroundSelf-citationBiomarker-driven and molecular targeted therapies for colorectal cancers
Schirripa, M., Cohen, S. A., Battaglin, F., & Lenz, H. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.06.003 · Cited by 27
Genetic, Epidemiological, Clinical, and Therapeutic Trajectories in Colon and Rectal Cancers
Capuozzo, M., Picone, C., Sabbatino, F., Santorsola, M., Caraglia, F., Iervolino, D., Sirica, R., Gualillo, O., Mauro, G. D., Castiello, R., et al. (2025) · Cancers · doi:10.3390/cancers17213438 · Cited by 28
“As the lesion enlarges, further mutations frequently affect oncogenes such as KRAS , enhancing proliferative signaling and supporting the transition to more advanced adenomas with high-grade dysplasia [93].”
Miladi-Abdennadher, I., Abdelmaksoud‐Dammak, R., Ayadi, L., Khabir, A., Frikha, F., Kallel, L., Frikha, M., Sellami‐Boudawara, T., Gargouri, A. F., & Mokdad‐Gargouri, R. (2010) · Bioscience Reports · doi:10.1042/bsr20100023 · Cited by 19
Bond, C., Nancarrow, D. J., Wockner, L. F., Wallace, L. M., Montgomery, G. W., Leggett, B., & Whitehall, V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091739 · Cited by 21
“The majority of sporadic CRC are BRAF wild type and arise from conventional adenomas that follow a well defined pathway of molecular events leading to cancer [12].”
BackgroundInfluentialGrowth Factors and Oncogenes as Targets in Melanoma: Lost in Translation?
Kwong, L. N., Chin, L., & Wagner, S. N. (2007) · Advances in Dermatology · doi:10.1016/j.yadr.2007.07.015 · Cited by 20
Uribe, P., Wistuba, I. I., & González, S. (2009) · American Journal of Dermatopathology · doi:10.1097/dad.0b013e318185d205 · Cited by 19
“Previous reports in colorectal cancer have shown that the frequency of BRAF mutations is low, but mutations in these tumors have been linked to MSI and the deficiency in repairing mismatched bases in DNA in sporadic tumors, especially by epigenetic alteration of hMLH1.(31,64,65) Thus, it has been suggested that BRAF c…”
BackgroundResultDistribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer
Ličar, A., Cerkovnik, P., & Novaković, S. (2010) · Medical Oncology · doi:10.1007/s12032-010-9631-z · Cited by 19
“This also is in concordance with previously published observations by other authors that mutations in KRAS and BRAF are mutually exclusive [33].”
ResultTsao, D., Yang, M.-J., Chang, H.-J., Yen, L.-C., Chiu, H., Hsueh, E.-J., Chen, Y., & Lin, S. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.023 · Cited by 19
“Activating mutations of the ras family are among the most common genetic events of human tumorigenesis [6].”
BackgroundEstablishing a Biological Profile for Interval Colorectal Cancers
Cisyk, A. L., Singh, H., & McManus, K. J. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3210-7 · Cited by 24
BRAF mutation in colorectal carcinomas with signet ring cell component
Yalçın, S., & Öngürü, Ö. (2017) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2017.0053 · Cited by 19
Henderson, Y. C., Fredrick, M. J., & Clayman, G. L. (2007) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.133.8.810 · Cited by 19
“Others have detected the V600E mutation of BRAF in various human cancers, including melanoma (up to 66%),(15,16) ovarian carcinoma (up to 40%),(15,17) and colorectal carcinoma (up to 20%).(15,18) In PTC, the incidence of RET/ PTC rearrangements ranges from 2.”
BackgroundAcss2/HIF-2 signaling facilitates colon cancer growth and metastasis
Garcia, J. A., Chen, R., Xu, M., Comerford, S. A., Hammer, R. E., Melton, S. D., & Feagins, L. A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282223 · Cited by 21
Christenson, E. S., Tsai, H., Le, D. T., Jaffee, E. M., Dudley, J. C., Xian, R. R., Gocke, C. D., Eshleman, J. R., & Lin, M.-T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1193259 · Cited by 20
“V600E mutation and dMMR CRC shown in the previous studies (7, 8, 20, 26).”
BackgroundRzasa, P., Whelan, S., Farahmand, P., Cai, H., Guterman, I., Palacios-Gallego, R., Undru, S. S., Sandford, L., Green, C., Andreadi, C., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05331-x · Cited by 19
“Additional molecular features associated with right-sided colonic neoplasia include CpG island methylator phenotype (CIMP), microsatellite instability (MSI), and loss of TGF signaling 10 – 12, 14, 16 .”
Bennani, B., Gilles, S., Fina, F., Nanni, I., Ibrahimi, S. A., Riffi, A. A., Nejjari, C., Benajeh, D.-A., Abkari, M. E., Martin, P., et al. (2010) · The International Journal of Biological Markers · doi:10.5301/jbm.2010.6091 · Cited by 18
“BRAF, one of the RAF kinases, is frequently activated by mutation in human tumors, particularly melanomas (~60%) and colorectal tumors (~15%) (8-11).”
BackgroundActivation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas
Maniscalco, L., Millán, Y., Iussich, S., Denina, M., Sánchez‐Céspedes, R., Gattino, F., BIOLATTI, B., Sasaki, N., Nakagawa, T., Renzo, M. F. D., et al. (2013) · BMC Veterinary Research · doi:10.1186/1746-6148-9-80 · Cited by 18
BRAF gene is not mutated in plasma cell leukemia and multiple myeloma
Bonello, L., Voena, C., Ladetto, M., Boccadoro, M., Palestro, G., Inghirami, G., & Chiarle, R. (2003) · Leukemia · doi:10.1038/sj.leu.2403116 · Cited by 16
Boissière‐Michot, F., Frugier, H., Ho-Pun-Cheung, A., Lopez‐Crapez, E., Duffour, J., & Bibeau, F. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-1958-1 · Cited by 18
Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer
Fernandes, M. S., Sanches, J., & Seruca, R. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02771-1_4 · Cited by 19
Serrated Polyps: Clinical Implications and Future Directions
Tadros, M., & Anderson, J. C. (2013) · Current Gastroenterology Reports · doi:10.1007/s11894-013-0342-4 · Cited by 18
Identification of driver modules in pan-cancer via coordinating coverage and exclusivity
Gao, B., Li, G., Liu, J., Li, Y., & Huang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.16433 · Cited by 17
“According to the existing knowledge, a driver pathway module usually exhibits two combinatorial properties: high coverage and high exclusivity [1, 2, 14, 15].”
BackgroundColorectal Liver Metastases: Does the Future of Precision Medicine Lie in Genetic Testing?
Barbon, C., Margonis, G. A., Andreatos, N., Rezaee, N., Sasaki, K., Buettner, S., Damaskos, C., Pawlik, T. M., He, J. P., Wolfgang, C. L., et al. (2018) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-018-3766-1 · Cited by 19
“On the contrary, KRAS mutations occur less commonly in this patient population.(87)”
BackgroundIkenoue, T., Kanai, F., Hikiba, Y., Tanaka, Y., Imamura, J., Ohta, M., Jazag, A., Guleng, B., Asaoka, Y., Tateishi, K., et al. (2005) · Molecular Carcinogenesis · doi:10.1002/mc.20102 · Cited by 18
“Approximately 10% of the cancer-associated B-raf mutations were found in the G loop [8].”
BackgroundTetzlaff, M. T., LiVolsi, V. A., & Baloch, Z. W. (2006) · Advances in Anatomic Pathology · doi:10.1097/01.pap.0000213044.23823.d3 · Cited by 19
“Primary malignant melanomas harbor B-RAF mutations at a frequency of 60% to 67%,(17,19) and colorectal cancers are affected in approximately 10% to 12% of all cases sampled.(17,18) More recently, PTCs and their anaplastic derivatives have been shown to contain B-RAF mutations at a frequency of 44% and 24%, respectivel…”
BackgroundBiology of Ras in Thyroid Cells
Meinkoth, J. L. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-4020-8107-3_7 · Cited by 18
The Serrated Polyp Comes of Age
Lauwers, G. Y., & Chung, D. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.035 · Cited by 18
Huang, J., Chan, P. S.-F., Pang, T. W.-Y., Choi, P., Chen, X., Lok, V., Zheng, Z., & Wong, M. C. S. (2021) · Endoscopy International Open · doi:10.1055/a-1333-1776 · Cited by 17
“Early molecular alterations in serrated lesions are BRAF and KRAS mutations [46].”
CBFB-MYH11 Fusion Sequesters RUNX1 in Cytoplasm to Prevent DNMT3A Recruitment to Target Genes in AML
Liu, P., Liu, J.-P., Sun, S.-J., Gao, Y., Ai, Y., Chen, X., Sun, Y., Zhou, M., Liu, Y., Xiong, Y., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.675424 · Cited by 19
Comparative Genomic Analysis and Clinical Outcomes of BRAF -mutated Advanced Biliary Tract Cancers
Tang, T., Nichetti, F., Kaplan, B., Lonardi, S., Pietrantonio, F., Salvatore, L., Vivaldi, C., Rimassa, L., de Braud, F., Rizzato, M. D., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1926 · Cited by 18
Ikenoue, T., Hikiba, Y., Kanai, F., Ijichi, H., Togo, G., Ohta, M., Watabe, H., Yamaji, Y., Okamoto, M., Aragaki, J., et al. (2004) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00299-1 · Cited by 17
Sudoyo, A. W., Kurniawan, A. N., Kusumo, G. D., Putra, T. P., Rexana, F., Yunus, M., Budiyati, A. D., Kurniawan, D., Utama, A., & Utomo, A. R. H. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.11.3421 · Cited by 19
KRAS and BRAF mutational status in colon cancer from Albanian patients
Martinetti, D., Costanzo, R., Kadare, S., Alimehmeti, M., Colarossi, C., Canzonieri, V., Berretta, M., & Memeo, L. (2014) · Diagnostic Pathology · doi:10.1186/s13000-014-0187-7 · Cited by 17
Qiu, W., Xia, X., Qiu, Z., Guo, M., & Yang, Z. (2017) · Gene · doi:10.1016/j.gene.2017.08.024 · Cited by 18
“2010), which has been found to play important roles in tumorigenesis and development of various cancers, including thyroid cancer (Rajagopalan et al. 2002; Melillo et al. 2005).”
BackgroundLaurent‐Puig, P., Agostini, J., & Maley, K. (2010) · Bulletin du Cancer · doi:10.1684/bdc.2010.1216 · Cited by 32
Wisdom, R., Huynh, L., Hsia, D. A., & Kim, S. (2005) · Oncogene · doi:10.1038/sj.onc.1208870 · Cited by 17
“…with active Ras (van Aelst et al., 1993; Vojtek et al., 1993), and genetic data argue strongly that, at least in fibroblasts and colon cancer cells, Raf is the dominant oncogenic effector of active Ras (Khosravi-Far et al., 1996; Marshall, 1996; Rajagopalan et al., 2002; Rangarajan et al., 2004).”
BackgroundNagy, A., Bálint, I., & Kovács, G. (2003) · International Journal of Cancer · doi:10.1002/ijc.11305 · Cited by 17
Olivero, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng033 · Cited by 17
“The MSI+ subset of sporadic colorectal cancers have a lower incidence of K-RAS mutation but a higher incidence of B-RAF mutation than tumours showing no defect in the mismatch repair system (24).”
The Case‐Only Odds Ratio as a Causal Parameter
Rosenbaum, P. R. (2004) · Biometrics · doi:10.1111/j.0006-341x.2004.00154.x · Cited by 16
“To be specific, consider the complementary roles proposed by Rajagopalan et al. (2002) for K-ras and B-raf mutations in colorectal cancers.”
BackgroundKRAS discordance between primary and recurrent tumors after radical resection of colorectal cancers
Lee, K. H., Kim, J. S., Lee, C. S., & Kim, J. (2015) · Journal of Surgical Oncology · doi:10.1002/jso.23936 · Cited by 19
Colorectal cancer: Review of signaling pathways and associated therapeutic strategies
Leiphrakpam, P. D., Rajappa, S. J., Krishnan, M., Batra, R., Murthy, S. S., & Are, C. (2023) · Journal of Surgical Oncology · doi:10.1002/jso.27295 · Cited by 18
“The BRAF gene, which encodes a serine‐threonine protein kinase, is activated by its interaction with RAS‐GTP.29 BRAF gene is mutated in up to 12% of CRC, and the majority of these mutations resulted in valine‐to‐ glutamic acid amino acid (V600E) substitution within the kinase activation domain of the BRAF protein.30 T…”
BackgroundKoga, Y., Hirahashi, M., Ohishi, Y., & Oda, Y. (2019) · Pathology International · doi:10.1111/pin.12803 · Cited by 21
Onozato, W., Yamashita, K., Yamashita, K., Kuba, T., Katoh, H., Nakamura, T., Sato, T., Ihara, A., Okayasu, I., & Watanabe, M. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21710 · Cited by 18
“This may have been caused by B-raf mutation, which has a dismal prognosis in microsatellite-stable CRC [47], and such cases can be included in YCC without K-ras mutation.”
BackgroundInfluential4-Anilino-7-alkenylquinoline-3-carbonitriles as potent MEK1 kinase inhibitors
Berger, D. M., Dutia, M. D., Powell, D. W., Floyd, M. B., Torres, N., Mallon, R. G., Wojciechowicz, D. C., Kim, S., Feldberg, L. R., Collins, K. C., et al. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.09.009 · Cited by 16
MicroRNA-486-3p directly targets BIK and regulates apoptosis and invasion in colorectal cancer cells
Li, F., Li, J., Han, J., Wang, G., Liu, Y., Zhang, X., Wang, Y., Wang, F., Ma, H., & Liu, Y. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s180354 · Cited by 18
Heat Shock Protein 90: The Cancer Chaperone
Neckers, L. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6401-2_12 · Cited by 18
KRAS Signaling Pathway Alterations in Microsatellite Unstable Gastrointestinal Cancers
Velho, S., Corso, G., Oliveíra, C., & Seruca, R. (2010) · Advances in cancer research · doi:10.1016/b978-0-12-380890-5.00004-1 · Cited by 18
Gau, L., Ribeiro, M., Pereira, B., Poirot, K., Dupré, A., Pezet, D., & Gagnière, J. (2021) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2021.05.039 · Cited by 15
Bayesian networks elucidate complex genomic landscapes in cancer
Angelopoulos, N., Chatzipli, A., Nangalia, J., Maura, F., & Campbell, P. J. (2022) · Communications Biology · doi:10.1038/s42003-022-03243-w · Cited by 23
“…explanations for the former are pathway redundancy, such as the mutual exclusivity of mutations on drivers in the RAS pathway ( BRAF and KRAS ) in colorectal cancer 2 and the RTK/RAS/PI3K pathway in hepatocellular carcinoma (with 22 – 37% of patients presenting at least one alteration) 3,4 .”
BackgroundOncogenic signaling is coupled to colorectal cancer cell differentiation state
Sell, T., Klotz, C., Fischer, M. M., Astaburuaga-García, R., Krug, S. M., Drost, J., Clevers, H. C., Sers, C., Morkel, M., & Blüthgen, N. (2023) · The Journal of Cell Biology · doi:10.1083/jcb.202204001 · Cited by 15
“Constitutive activation of the EGFR/MAPK pathway components KRAS and BRAF occurs in 40 and 5 – 10% of CRCs, respectively, and promotes proliferation among other functions (Cancer Genome Atlas Network, 2012; Rajagopalan et al., 2002).”
Xiao, D., Chen, T., Zhang, T., Shi, S., Zhang, M., Qin, X., Liu, Y., Li, L., & Lin, Y. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108602 · Cited by 15
Targeted therapy in advanced colorectal cancer: more data, more questions
Ochenduszko, S. L., & Krzemieniecki, K. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833cfc99 · Cited by 16
Kim, S. T., Ahn, T. J., Lee, E., Do, I., Lee, S. J., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Kang, W. K., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1759-y · Cited by 16
“alterations such as mutations in BRAF and PIK3CA were identified as candidates associated with resistance to anti-EGFR therapies in wild type KRAS patients [8, 10–13].”
BackgroundCheckpoint molecules on infiltrating immune cells in colorectal tumor microenvironment
Talaat, I. M., Elemam, N. M., Zaher, S., & Saber-Ayad, M. M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.955599 · Cited by 17
Analysis of K‐ras, BRAF, and PIK3CA mutations in laterally‐spreading tumors of the colorectum
Kaji, E., Kato, J., Suzuki, H., Akita, M., Horii, J., Saito, S., Higashi, R., Ishikawa, S., Kuriyama, M., Hiraoka, S., et al. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06485.x · Cited by 16
García‐Albéniz, X., Pericay, C., Alonso‐Espinaco, V., Alonso, V., Escudero, P., Fernández-Martos, C., Gallego, R., Gascón, P., Castellví-Bel, S., & Maurel, J. (2010) · Tumor Biology · doi:10.1007/s13277-010-0136-3 · Cited by 15
“KRAS and BRAF mutations seem to be mutually exclusive, supporting the idea that they exert equivalent effects in tumorigenesis [15].”
BackgroundMarshall, J. L. (2009) · Journal of Oncology · doi:10.1155/2009/937305 · Cited by 18
“Consistent with previous studies [56, 59], BRAF mutations were observed only in tumors with wild-type KRAS.”
Chow, A. K.-M., Cheng, N. S.-M., Lam, C. S., Ng, L., Wong, S. K., Wan, T. M.-H., Man, J. H.-W., Cheung, A. H. K., Yau, T. C. C., Poon, J. T. C., et al. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0352-y · Cited by 15
RetractedCohen, R., Svrcek, M., Dreyer, C., Cervera, P., Duval, A., Pocard, M. D., Fléjou, J., de Gramont, A., & André, T. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0504-2 · Cited by 16
“BRAF V600E mutation is strongly associated with dMMR (20%70% of dMMR tumors versus 5-10% of pMMR tumors) [18,29] and indicates a sporadic origin [30].”
BackgroundYosef, H. K., Frick, T., Hammoud, M. K., Maghnouj, A., Hahn, S. A., Gerwert, K. B., & El‐Mashtoly, S. F. (2018) · The Analyst · doi:10.1039/c8an02029a · Cited by 18
Metadata
- Authors
- Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E.
- Affiliations
- Johns Hopkins University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Velculescu, Victor E.
- Venue
- Nature
- Published
- 2002-08-29
- Volume
- 418
- Issue
- 6901
- Pages
- 934-934
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985035689
- Cited by
- 1,224
- References
- 8
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 29 · 2023: 30 · 2022: 26 · 2021: 42 · 2020: 38 · 2019: 35 · 2018: 41 · 2017: 42 · 2016: 51 · 2015: 76 · 2014: 65 · 2013: 74 · 2012: 78
- FWCI
- 37.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- BRAF mutation, KRAS mutation, oncogenic Ras, DNA mismatch repair, colorectal cancer, melanoma, carcinogenesis, DNA repair, mutation spectrum, growth factor signaling
- MeSH terms
- DNA Damage, DNA Repair, Gene Frequency, Humans, Mutation, Oncogenes, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins c-raf, Base Pair Mismatch
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.